Needled wrote:Just my 2 cents, which is worth absolutely nothing.
No, it's worth at least 2 cents.
Actually I think your posts are much more valuable than that.
I absolutely agree that the oral meds will probably be priced much higher than they should. And I agree with Harry, that we will probably be treated to more wasteful "which drug is better" studies, similar to the Rebif/Avnoex/Copaxone marketing battles. I can see it now: "Cladribine is only taken 6 times a year, and studies show it's the most convenient. Yeah, but Fingolimod has a greater reduction in relapses for males aged 23 to 24, and besides Cladribine causes cancer."
I was only referring to the idea that the CRAB makers will try to defend the injectables over the pills. Since they are all trying to get a pill to market anyway, this can't hold water for too long.
Well, at least in their prescribing information, the drug makers can say this drug works by suppressing the hell out of the immune system, instead of "we don't really know how this drug works."